Canada, like many countries, relies heavily on the global market, of which the U.S. paid plasma industry plays the largest role,to procure plasma-derived drugs for Canadian patients. Without this system, there would be severe product shortages in Canada and around the globe. Canada, like other nations, is looking to increase the amount of plasma collected domestically to off-set this increasingly disproportionate reliance on the U.S.
To mitigate the fast-growing global risks to plasma sufficiency and associated plasma protein product shortages, we must continue to adapt our plasma collection plans.
We are seeing an increased use of these products as a result of advances in medicine that allow health care professionals to better diagnose patients, and as new medical uses are discovered.
Increasing the amount of source plasma collected through the networked national system that Canadian Blood Services manages and controls, is crucial to addressing the needs of patients and moderating the related impacts to Canada’s healthcare system, today and into the future.